Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes

Sponsor
Sun Yat-sen University
Study ID
NCT07003191
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The main objective of this study is to evaluate the efficacy and safety of Metformin Hydrochloride and Empagliflozin Tablets in the treatment of type 2 diabetes in real-world clinical settings. A total of 2,600 type 2 diabetes patients were included in the study. The study observed the clinical glycemic control rate and adverse events over a period of at least 6 months from the prescription date to the end of continuous clinical follow-up.

Key Dates

Start date
Aug 2, 2023
Status verified
May 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
2,600 participants (estimated)

Primary Outcome Measure

6-month clinical glycemic control rate [ Time Frame: 6 months ]

Related Studies